Abnormal Natural Killer Cell Function in Systemic Sclerosis: Altered Cytokine Production and Defective Killing Activity  by Horikawa, Mayuka et al.
Abnormal Natural Killer Cell Function in Systemic Sclerosis:
Altered Cytokine Production and Defective Killing Activity
Mayuka Horikawa, Minoru Hasegawa, Kazuhiro Komura, Ikuko Hayakawa, Koichi Yanaba,
Takashi Matsushita, Kazuhiko Takehara, and Shinichi Satow
Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan; wDepartment of Dermatology, Nagasaki University
Graduate School of Biomedical Sciences, Nagasaki, Japan
Natural killer (NK) cells are innate immune effectors that produce various immunoregulatory cytokines. Recent
studies have shown that NK cells are involved in the initiation of autoimmunity. In this study, we determined
abnormalities of NK cells in systemic sclerosis (SSc), an autoimmune connective tissue disease, by assessing the
frequency and absolute number, activation marker expression, cytokine production, and killing activity. The fre-
quency and absolute number of NK cells increased in diffuse cutaneous SSc (dcSSc), whereas they were normal in
limited cutaneous SSc (lcSSc). NK cells from both dcSSc and lcSSc patients exhibited activated phenotypes
characterized by up-regulated CD16 and CD69 expression and downregulated CD62L expression. Interferon (IFN)-c
production by non-stimulated NK cells from both dcSSc and lcSSc patients was increased compared to the normal
control, whereas on stimulation, a reduced amount of IFN-c was produced. Interleukin (IL)-5 and IL-10 production
by non-stimulated NK cells and IL-6 production by stimulated NK cells were augmented in dcSSc patients, but not
in lcSSc patients. Despite the augmented cytokine production by non-stimulated NK cells, natural cytotoxicity
activity and granzyme B secretion was reduced in NK cells from dcSSc and lcSSc patients. These results suggested
that altered NK cell function contributes to immunological abnormalities in SSc.
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Systemic sclerosis (SSc) is a connective tissue disease
characterized by increased collagen production by fibro-
blasts, resulting in cutaneous and internal organ fibrosis,
with an autoimmune background. One of the central fea-
tures in SSc is the presence of a variety of immunological
abnormalities, such as in vivo T lymphocyte activation,
elevated serum levels of various cytokines and growth
factors, chronic activation of memory B lymphocytes, the
frequent occurrence of autoantibodies, and hyper-g-globu-
linemia (White, 1996; Sato et al, 2004). Although the patho-
genesis of SSc remains unknown, these immunological
abnormalities play an important role in the initiation and
development of this disease.
Natural killer (NK) cells are characterized by their ability
to lyse transformed cells and virally infected cells without
antigen sensitization, thereby contributing to the early host
defense of innate immunity (Biron et al, 1999; Seaman,
2000). In recent years, other functions of NK cells have been
identified, particularly their capacity to produce various
cytokines (Biron et al, 1999; Seaman, 2000). NK cells pro-
duce not only T helper type 1 (Th1) cytokines such as
interferon (IFN)-g, tumor necrosis factor (TNF)-a, and gran-
ulocyte-macrophage colony stimulating factor, but also Th2
cytokines such as interleukin (IL)-5, IL-10, and IL-13 and
other cytokines such as transforming growth factor (TGF)-b
(Peritt et al, 1998; Biron et al, 1999; Seaman, 2000; Shi et al,
2001). Thus, NK cells are able to regulate immune respons-
es either directly or indirectly through cytokine secretion
(Peritt et al, 1998; Biron et al, 1999; Seaman, 2000; Shi et al,
2001). It has been revealed that NK or NK1.1þ T (NKT) cells
are involved in various experimental autoimmune diseases
(Maruyama et al, 1991; Zhang et al, 1997; Fort et al, 1998).
Although the effects of NK cells were not distinguished from
those of NKT cells in these studies (Shi et al, 2001), a recent
study has shown that NK cells, but not NKT cells, promote
the development of murine myasthenia gravis, a T cell-de-
pendent, B cell- and autoantibody-mediated autoimmune
disease (Shi et al, 2000). In this model, the requirement for
NK cells is reflected by the lack of a Th1 response and
autoantibodies, suggesting that NK cells regulate auto-re-
active T and B cells (Shi et al, 2000).
NK cell abnormalities have been reported in SSc with
conflicting results (Wright et al, 1982; Majewski et al, 1987;
Miller et al, 1988; Grazia Cifone et al, 1990; Kantor et al,
1992). Specifically, the killing activity of NK cells from SSc
patients was decreased in three previous studies (Wright
et al, 1982; Majewski et al, 1987; Miller et al, 1988), whereas
it was enhanced in two studies (Grazia Cifone et al, 1990;
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Wanchu et al, 1995). One study showed normal killing
activity in SSc (Kantor et al, 1992). Two studies showed the
normal frequency and absolute number of circulating NK
cells in SSc (Miller et al, 1988; Kantor et al, 1992), whereas
one study showed increased NK cell frequency (Grazia Cif-
one et al, 1990). In all these studies, the NK cell killing ac-
tivity was assessed with total peripheral blood mononuclear
cells (PBMC), but not with isolated NK cells. Since NK ac-
tivity is proportional to the percentage of NK cells (Ichikawa
et al, 1985), the discrepancy among killing activity results
may be due to different NK cell numbers. In addition, the
presence of other lymphocytes in PBMC might affect NK
cell killing. Furthermore, the analysis of cell surface activa-
tion marker expression on NK cells and cytokine production
by NK cells from SSc patients were not analyzed in any of
the previous studies.
In this study, to determine NK cell dysfunction in SSc,
we assessed the percentage and number of blood NK cells,
activation marker expression, and production of cytokine
and granzyme B, and natural cytotoxicity by isolated NK
cells from SSc patients.
Results
Frequency and absolute number of NK cells The fre-
quency and absolute number of NK cells in blood from SSc
patients and normal individuals were examined by flow
cytometry. The NK cell frequency in dcSSc patients was
significantly increased relative to lcSSc patients (po0.0001)
and normal controls (po0.001; Fig 1A). Similarly, the abso-
lute number of NK cells in dcSSc patients was significantly
increased compared to normal controls (po0.05; Fig 1B).
By contrast, there was no significant difference in the NK
cell frequency and number between lcSSc patients and
normal controls, although some patients with lcSSc showed
relatively high numbers of NK cells.
Expression of CD16, CD25, CD54, CD62L, CD69, and
CD95 on NK cells To assess the NK cell activation state,
the expression of CD16, CD25, CD54, CD62L, CD69, and
CD95 was analysed with flow cytometry (Figs 2 and 3).
CD56þ NK cells in dcSSc and lcSSc patients exhibited
significantly higher CD16 expression levels than normal
controls (po0.05). The frequency of cells expressing CD69,
an early activation marker, in CD56þ NK cells was signif-
icantly increased in dcSSc and lcSSc patients compared
with normal controls (po0.001 and po0.005, respectively).
The frequency of CD62L expression on NK cells was sig-
nificantly decreased in dcSSc and lcSSc patients than in
normal controls (po0.001 and po0.005, respectively), in-
dicating that NK cells from SSc patients are activated since
NK cell activation results in the loss of CD62L (L-selectin) ex-
pression (Frey et al, 1998). There was no significant differ-
ence in the frequency of NK cells expressing CD25, CD54, or
CD95 and the expression levels of these molecules between
SSc patients and normal controls (data not shown). There-
fore, NK cells from SSc patients exhibited an activated
phenotype characterized by up-regulated CD16 and CD69
expression and down-regulated CD62L expression.
Cytokine production by NK cells The production of IFN-g,
IL-5, IL-6, IL-10, and IL-13 by NK cells stimulated with or
without phorbol 12-myristate 13-acetate (PMA) and ion-
omycin was examined by ELISA (Fig 4). IFN-g production by
non-stimulated NK cells form dcSSc and lcSSc patients
was significantly increased 3–5-fold compared to normal
controls (po0.005). By contrast, on stimulation, NK cells
from dcSSc and lcSSc patients produced a significantly,
 40%, lower amount of IFN-g than from normal controls
(po0.05 and po0.01, respectively). IFN-g production by
non-stimulated or stimulated NK cells did not significantly
differ between dcSSc and lcSSc patients. Non-stimulated
NK cells from dcSSc patients produced a significantly,
3–4-fold, larger amount of IL-5 than from lcSSc patients
(po0.005) or normal controls (po0.005); however, no such
significance difference was observed after stimulation. Non-
stimulated NK cells from dcSSc and lcSSc patients pro-
duced a normal IL-6 amount, whereas stimulated NK cells
from dcSSc patients released a significantly, 2.6-fold, larger
amount of IL-6 relative to normal controls (po0.005). IL-10
production by non-stimulated NK cells was detected in
seven of ten dcSSc patients, whereas it was detected in only
one of nine lcSSc patients and none of the normal controls.
After stimulation, IL-10 production was detected in four of
ten dcSSc patients and three of nine lcSSc patients, where-
as it could not be detected in the normal controls. IL-13
production could not be detected from either non-stimulated
or activated NK cells from SSc patients and healthy controls.
Thus, dcSSc patients generally exhibited enhanced produc-
tion of IL-5, IL-6, and IL-10 by NK cells compared with lcSSc
Figure1
Frequency and absolute number of pe-
ripheral blood natural killer (NK) cells in
diffuse cutaneous systemic sclerosis
patients, limited cutaneous systemic
sclerosis patients, and normal controls
(CTL). The frequency of NK cells was de-
termined as CD56þ cells by immunoflu-
orescence staining with flow cytometric
analysis (A). Absolute numbers of NK cells
were calculated from the relative frequen-
cy of NK cells and the absolute leukocyte
(B). The horizontal bars represent mean
values with statistically significant differ-
ences between groups indicated.
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patients, except that altered IFN-g production was similarly
detected in both dcSSc and lcSSc patients.
Natural cytotoxicity of NK cells To further investigate the
functional abnormalities of SSc NK cells, we examined NK
cell killing activity by performing a cell-mediated cytotox-
icity assay with flow cytometric analysis, which has been
widely used to determine cytotoxicity instead of the stand-
ard 51Cr release assay (Chang et al, 1993; Hoppner et al,
2002). This two-color fluorescence assay allows direct as-
sessment of cell-mediated cytotoxicity measurements that
correlate well with those obtained using conventional 51Cr
release assays (Chang et al, 1993). Isolated NK cells
from SSc patients had 10%–20% reduction in their ability
to lyse K562 target cells compared with normal controls
at all E:T ratios (po0.05; Fig 5). There was no significant
difference in the killing activity between dcSSc and lcSSc
patients.
Granzyme B secretion by NK cells Granzyme B, a
serine protease, is present in cytoplasmic granules of NK
cells and is involved in natural cytotoxicity by NK cells
Figure 2
CD16, CD69, and CD62L expression on
CD56þ natural killer (NK) cells in diffuse
cutaneous systemic sclerosis (dcSSc)
patients, limited cutaneous systemic
sclerosis (lcSSc) patients, and normal
controls (CTL). For CD16 expression lev-
els on NK cells, two-color analysis was
performed using fluorescein isothiocyan-
ate (FITC)-conjugated anti-CD16 and
phycoerythrin (PE)-conjugated anti-CD56
monoclonal Abs (mAb). For the expression
of CD69 and CD62L, two-color analysis
was conducted using a combination of
FITC-conjugated anti-CD56 and PE-conju-
gated either anti-CD69 or anti-L-selectin
mAb. All samples were analyzed by flow
cytometry with identical instrument set-
tings. Horizontal dashed lines are provided
for reference. The number in each quad-
rant represents a percentage of all lymph-
ocytes. The numbers beside the square
represent the number of cells within each
square as a percentage of all CD56þ NK
cells. Representative histograms of dcSSc
patients, lcSSc patients, and CTL are shown.
Figure 3
CD16 expression level, CD69, and CD62L frequency on natural killer (NK) cells from diffuse cutaneous systemic sclerosis patients, limited
cutaneous systemic sclerosis patients, and normal controls (CTL). CD16 expression levels on CD56þ NK cells (A) and frequency of CD69þ
cells (B) and CD62L (C) in CD56þ NK cells were determined by flow cytometric analysis as described in Fig 2. The horizontal bars represent mean
values with statistically significant differences between groups indicated.
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(Seaman, 2000). Therefore, granzyme B released by isolat-
ed NK cells was assessed by ELISA (Fig 6). Granzyme B
released by unstimulated NK cells was  40% significantly
lower in lcSSc or dcSSc patients than in normal controls
(po0.05). Furthermore, NK cells stimulated by PMA and
ionomycin produced a significant reduction in granzyme B
release in lcSSc patients compared to normal controls
(po0.05), whereas granzyme B production by stimulated
NK cells was similar between dcSSc patients and normal
controls.
Discussion
In this study, an activated phenotype was observed in cir-
culating NK cells from both dcSSc and lcSSc patients, with
a more activated phenotype in dcSSc NK cells. CD69 ex-
pression on SSc NK cells was upregulated, whereas CD25
expression was normal. This may be explained by the find-
ing that CD69 expression is increased in very early phase of
activation, whereas CD25 expression is up-regulated in late
phase (Marzio et al, 1999; Reddy et al, 2004). Indeed, CD25
Figure 4
Cytokine production by natural killer
(NK) cells from diffuse cutaneous sys-
temic sclerosis patients, limited cuta-
neous systemic sclerosis patients, and
normal controls (CTL). Purified NK cells
(0.5  105) were stimulated with either
medium alone (non-stimulated) or phorbol
12-myristate 13-acetate and ionomycin
(stimulated) for 24 h. Cell supernatants
were analyzed by ELISA to determine the
levels of interferon-g, interleukin (IL)-5, IL-
6, and IL-10. The horizontal bars represent
mean values with statistically significant
differences between groups indicated.
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and CD69 expression on NK cells is inversely correlated
(Clausen et al, 2003). Both dcSSc and lcSSc patients ex-
hibited abnormal function of NK cells characterized by al-
tered cytokine production, diminished natural cytotoxicity,
and decreased granzyme B release. The frequency and
absolute number of NK cells were increased in dcSSc
compared to normal controls. This NK cell expansion may
be related to increased serum levels of IL-2 and IL-15,
cytokines that can induce NK cell proliferation, in SSc pa-
tients (Needleman et al, 1992; Suzuki et al, 2001), Further-
more, augmented IL-5 by non-stimulated NK cells and IL-6
production by stimulated NK cells were increased in dcSSc,
but not in lcSSc. IL-5 promotes the proliferation and differ-
entiation of eosinophils that stimulate matrix production in
dermal fibroblasts (Birkland et al, 1994). SSc patients with
active lung fibrosis exhibit a higher frequency of eosinophils
in their bronchoalveolar lavage fluid, and bronchoalveolar
lavage cells express higher IL-5 levels (Atamas et al, 1999),
suggesting that increased IL-5 production by NK cells in
dcSSc may be related to lung inflammation. IL-6 production
by PMBC and serum IL-6 levels are increased in dcSSc
patients, especially those with lung involvement (Bolster
et al, 1997; Hasegawa et al, 1998; Scala et al, 2004). Con-
sistently, in our study, eight of ten dcSSc patients but no
lcSSc patients examined had lung fibrosis. Thus, the in-
creased IL-5 and IL-6 production by dcSSc NK cells might
contribute to the more severe clinical manifestations.
The results of previous studies regarding natural cytotox-
icity abnormalities in SSc were conflicted, probably due to
the use of total PBMC as the NK cell source (Wright et al,
1982; Majewski et al, 1987; Miller et al, 1988; Grazia Cifone
et al, 1990; Kantor et al, 1992; Wanchu et al, 1995). This study
using isolated NK cells showed that cytotoxicity activity by
SSc NK cells was constitutively reduced, excluding the ef-
fects of different NK cell numbers and other lymphocytes in
PBMC. This diminished cytotoxicity activity by SSc NK cells
may be explained in part by reduced granzyme B release,
since granzyme B secretion correlates with cytotoxicity ac-
tivity evaluated by the standard 51Cr-release cytotoxicity
assay (Rininsland et al, 2000; Shafer-Weaver et al, 2003).
Alternatively, chronic NK cell activation in SSc may prevent
efficient activation when active killing is required.
A recent study has shown that human NK cells are able
to polarize in vitro into two functionally distinct subsets, NK
type 1 (NK1) and NK2, analogous to T-cell subsets Th1 and
Th2 (Peritt et al, 1998). NK1 cells mainly produce IFN-g
and IL-10, whereas NK2 cells predominantly produce IL-5 and
IL-13 (Peritt et al, 1998). In SSc, it has been reported that
serum levels and production levels by stimulated PBMC of
Th2 cytokines, such as IL-4, IL-6, and IL-13, are increased,
suggesting that SSc may be a Th2-predominant disease
(Needleman et al, 1992; Hasegawa et al, 1997). Recent
studies, however, have shown that Th1 cytokine production
is also increased in SSc. Serum levels of IL-12, a potent
inducer of Th1 cells, are elevated in SSc patients (Sato et al,
2000). The finding that NK cells produced a larger amount of
Th2 cytokines (IL-5, IL-6, and IL-10) in dcSSc suggests NK2
response activation. In contrast, IFN-g production by non-
stimulated NK cells in dcSSc and lcSSc was significantly
increased, which suggests NK1 response activation. NK1
Figure 5
Natural cytotoxicity by natural killer (NK) cells. Cytotoxicity activity
of NK cells from diffuse cutaneous systemic sclerosis patients, limited
cutaneous systemic sclerosis patients, and normal controls (CTL) was
assessed by flow cytometry. The K562 target cells stained with DiOC18
were mixed with isolated NK cells at effector:target (E:T) ratios of 5:1,
10:1, 20:1, and 40:1. Propidium iodide was then added to the mixture
and incubated at 371C for 2 h. Two-color flow cytometric analysis was
performed to assess NK lytic activity. Percent cytotoxicity was calcu-
lated by the frequency of dead propidium iodide-positive target cells
divided by the total target cells stained with DiOC18.
Figure 6
Granzyme B secretion by natural killer
(NK) cells from diffuse cutaneous sys-
temic sclerosis patients, limited cuta-
neous systemic sclerosis patients, and
normal controls (CTL). Purified NK cells
(0.5  105) were stimulated with either
medium alone (non-stimulated) or phorbol
12-myristate 13-acetate and ionomycin
(stimulated) for 24 h. Cell supernatants
were analyzed by ELISA to determine
granzyme B levels. The horizontal bars
represent mean values with statistically
significant differences between groups
indicated.
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cells produced high IFN-g levels when cocultured with IL-12
(Peritt et al, 1998). This elevated IFN-g production by non-
stimulated NK cells may result from increased serum IL-12
levels in SSc (Sato et al, 2000). Our results suggest that
both NK1 and NK2 responses occur in dcSSc. Thus, similar
to Th1/Th2 responses, NK1/NK2 responses appear to
be complicated, and activation of each response may vary
according to various factors, including NK cell activation
status and disease subsets.
Although a possible link between NK cell abnormalities
and SSc has long been suggested, research has focus on
NK cell cytotoxic activity. This study reveals distinct abnor-
malities in various aspects of NK cell functions in SSc.
Therefore, the analysis of NK cells from this viewpoint would
provide an important clue for further understanding immu-
nological abnormalities and their relevance to clinical man-
ifestations in SSc.
Patients and Methods
Patients and controls for ﬂow cytometric analysis Blood
samples were obtained from 46 Japanese patients with SSc (44
females and two males). All patients fulfilled the criteria by the
American College of Rheumatology (Subcommittee for Scleroder-
ma Criteria of the American Rheumatism Association Diagnostic
and Therapeutic Criteria Committee, 1980). Localized scleroderma
and morphea patients were excluded in this study. These SSc pa-
tients were grouped according to the classification system pro-
posed by LeRoy et al (1988): 31 patients (all females) had lcSSc
and 15 patients (13 females and two males) had dcSSc. According
to the Barnett et al (1988) classification, SSc patients were clas-
sified into 13 patients with type 1 (sclerodactyly only), 25 with type
2 (sclerosis proximal to the metacarpophalangeal joints but ex-
cluding the trunk), and eight with type 3 (diffuse skin sclerosis
including the trunk). All type 1 patients were lcSSc, whereas all
type 3 patients belong to dcSSc. Type 2 patients consisted of 18
lcSSc and seven dcSSc patients. The age of patients with lcSSc
and dcSSc (mean  SD) was 54  11 and 49  16 y old, respec-
tively. The disease duration of patients with lcSSc and dcSSc was
10.4  8.2 and 6.1  5.3 y, respectively. None of the SSc patients
was treated with steroids, D-penicillamine, or other immunosup-
pressive therapy. The antinuclear antibody (Ab) was determined by
indirect immunofluorescence using HEp-2 cells as the substrate,
and autoantibody specificities were further assessed by ELISA and
immunoprecipitation. Anticentromere Ab was positive in 24 pa-
tients, anti-topoisomerase I Ab in ten, anti-U1RNP Ab infour, anti-
mitochondria Ab in one, anti-RNA polymerases I and III Ab in two,
and other unknown antinuclear Ab in two. The remaining three
patients were negative for autoantibody. Twenty age- and sex-
matched healthy Japanese individuals (19 females and one male
aged 49  10 y) were used as normal controls. The protocol was
approved by the Kanazawa University Graduate School of Medical
Science, and informed consent was obtained from all patients. The
study was conducted according to the Declaration of Helsinki
Principles.
Flow cytometric analysis Two-color analysis for NK cell percent-
age was performed using fluorescein isothiocyanate (FITC)-con-
jugated anti-CD16 (Beckman Coulter, Miami, Florida) and phycoer-
ythrin (PE)-conjugated anti-CD56 (Exalpha Biologicals, Boston,
Massachusetts) monoclonal Abs (mAb). For activation marker ex-
pression, two-color analysis was conducted using a combination
of FITC-conjugated anti-CD56 (Exalpha Biologicals) and PE-con-
jugated mAb, and anti-CD25 (Beckman Coulter), anti-CD54 (Beck-
man Coulter), anti-CD62L (Beckman Coulter), anti-CD69 (Beckman
Coulter), or anti-CD95 (Beckman Coulter). Fresh heparinized whole
blood samples were collected and immediately placed on ice.
Blood samples (50 mL) were stained at 41C using predetermined
saturating concentrations of the test mAb for 20 min as previously
described (Sato et al, 2004). Blood erythrocytes were lysed after
staining using a Coulter Whole Blood Immuno-Lyse kit as detailed
by the manufacturer (Beckman Coulter). Cells were analyzed on a
FACScan flow cytometer (BD PharMingen, San Diego, California).
Absolute numbers of cells were calculated from the relative fre-
quency of NK cells and the absolute lymphocyte counts.
NK cell isolation PBMC were separated using Ficoll–Paque
(Pharmacia Biotech, Uppsala, Sweden) after centrifugation. NK
cells were isolated from PBMC using a magnetic cell sorting NK-
cell-isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany),
according to the manufacturer’s recommendations. Briefly, non-NK
cells (T cells, B cells, monocytes, basophils, dendritic cells, plate-
lets, and early erythroid cells) were magnetically labeled using a
cocktail of biotin-conjugated mAbs to CD3, CD4, CD14, CD15,
CD19, CD36, CD123 and glycophorin A in combination with mag-
netic bead-conjugated anti-biotin mAb. The magnetically labeled
cells were depleted by retaining on a magnetic column. After iso-
lation, 495% of cells were CD56þ by flow cytometric analysis.
Cytokine and granzyme B production by NK cells The patients
analyzed for cytokine production by NK cells were different from
those described above: 21 SSc patients (17 females and 4 males
aged 57.6  10.1 y; 11 lcSSc patients and ten dcSSc patients) and
nine healthy individuals (six females and three males aged
41.3  12.5 y) for cytokine production and 16 healthy individuals
(12 females and four males aged 40.1  12.1 y) for granzyme B
production were examined. None of these patients was treated
with steroids, D-penicillamine, or other immunosuppressive thera-
py. Isolated NK cells (1  105) were suspended in RPMI 1640 me-
dium supplemented with 10% heat-inactivated fetal calf serum and
incubated in a 5% CO2 incubator with or without 25 ng per mL of
PMA and 1 mg per mL of ionomycin at 371C for 24 h. The culture
supernatant was collected, and levels of cytokines and granzyme
B were determined by ELISA specific for IFN-g (R&D Systems,
Minneapolis, Minnesota), IL-5 (R&D System), IL-6 (BD PharMin-
gen), IL-10 (BD PharMingen), IL-13 (R&D System), and granzyme B
(Euroclone Life Sciences, Pero, Italy), according to the manufac-
turer’s instructions.
Cytotoxicity assays The patients examined for analysis of cyto-
toxicity activity were different from those described above: 6 SSc
patients (6 females aged 52.6  11.0 y; 4 lcSSc and 2 dcSSc pa-
tients) and 3 healthy individuals (3 females aged 35  7.2 y) were
examined. None of these patients was treated with steroids, D-
penicillamine, or other immunosuppressive therapy. To assess the
cytotoxic activity of NK cells, K562, a human erythroleukemic cell
line, was used as the target cell. Cultures of K562 cells were split to
a concentration of 3  105 cells per mL 3 d prior to testing, to
ensure that cells were in the log phase. A cytotoxicity assay was
performed using a cell-mediated cytotoxicity kit (Molecular Probes,
Eugene, Oregon), according to the manufacturer’s instructions.
The target cells were stained with DiOC18 (Molecular Probes) for 20
min at 371C. The stained target cells (1  106 cells per mL) were
resuspended in culture medium and then mixed with isolated NK
cells to yield the desired effector:target (E:T) ratios of 40:1, 20:1,
10:1, and 5:1. A counterstaining solution containing propidium io-
dide, which detects dead cells, was added to the mixture and
incubated at 371C for 2 h. Two-color flow cytometric analysis was
performed to assess NK lytic activity. Percent lysis was calculated
by the frequency of dead target cells divided by the total target
cells. Spontaneous cell lysis as determined in the absence of ef-
fector cells was subtracted from total lysis to calculate the amount
of specific lysis.
Statistical analysis Statistical analysis was performed using the
Mann–Whitney U test to determine the level of significance of dif-
ferences between the sample means, and Bonferroni’s test was
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used for multiple comparisons. A p value less than 0.05 considered
statistically significant.
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